Florence Chaverneff, PhD

Medical Editor

Most Recent Articles by Florence Chaverneff, PhD

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

By

Eptinezumab has shown 100% bioavailability when administered intravenously.

Fremanezumab May Help Reduce Medication Overuse in Chronic Migraine

Fremanezumab May Help Reduce Medication Overuse in Chronic Migraine

By

Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.

Chronic Migraine Associated With Age-Related Changes in Cortical Thickness

Chronic Migraine Associated With Age-Related Changes in Cortical Thickness

By

Individuals with chronic migraine may present with age-related changes in cortical thickness.

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

By

Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

By

Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.

More Articles by Florence Chaverneff, PhD

Sign Up for Free e-newsletters



CME Focus